<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TALACEN- pentazocine hydrochloride and acetaminophen tablet </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<h1>TALACEN<span class="Sup">®</span><br>Pentazocine hydrochloride, USP,<br>and acetaminophen, USP.</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">CIV</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">TALACEN is a combination of pentazocine hydrochloride, USP, equivalent to 25 mg base and acetaminophen, USP, 650 mg.</p>
<p>Pentazocine is a member of the benzazocine series (also known as the benzomorphan series).  Chemically, pentazocine is (2R*, 6R*, 11R*)1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol, a white, crystalline substance soluble in acidic aqueous solutions, and has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=927F1BB9-6C13-4229-A5C8-0BF0B4C3BB35&amp;name=talacen-01.jpg"></div>
<p>Chemically, acetaminophen is Acetamide, <span class="Italics">N</span>-(4-hydroxyphenyl)-, and has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=927F1BB9-6C13-4229-A5C8-0BF0B4C3BB35&amp;name=talacen-02.jpg"></div>
<p>Pentazocine is an analgesic and acetaminophen is an analgesic and antipyretic.</p>
<p><span class="Italics">Inactive Ingredients</span>: Colloidal Silicon Dioxide, FD&amp;C Blue #1, Gelatin, Microcrystalline Cellulose, Potassium Sorbate, Pregelatinized Starch, Sodium Lauryl Sulfate, Sodium Metabisulfite, Sodium Starch Glycolate, Stearic Acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">TALACEN is an analgesic possessing antipyretic actions.</p>
<p>Pentazocine is an analgesic with agonist/antagonist action which when administered orally is approximately equivalent on a mg for mg basis in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> to codeine.</p>
<p>Acetaminophen is an analgesic and antipyretic.</p>
<p>Onset of significant <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with pentazocine usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer.  Onset and duration of action and the degree of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief are related both to dose and the severity of pretreatment <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  Pentazocine weakly antagonizes the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of morphine, meperidine, and phenazocine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> induced by morphine and meperidine.  Pentazocine has about 1/50 the antagonistic activity of nalorphine.  It also has sedative activity.</p>
<p>Pentazocine is well absorbed from the gastrointestinal tract.  Plasma levels closely correspond to the onset, duration, and intensity of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.  The time to mean peak concentration in 24 normal volunteers was 1.7 hours (range 0.5 to 4 hours) after oral administration and the mean plasma elimination half-life was 3.6 hours (range 1.5 to 10 hours).</p>
<p>The action of pentazocine is terminated for the most part by biotransformation in the liver with some free pentazocine excreted in the urine.  The products of the oxidation of the terminal methyl groups and glucuronide conjugates are excreted by the kidney. Elimination of approximately 60% of the total dose occurs within 24 hours.  Pentazocine passes the placental barrier.</p>
<p>Onset of significant analgesic and antipyretic activity of acetaminophen when administered orally occurs within 30 minutes and is maximal at approximately 2 1/2 hours.  The pharmacological mode of action of acetaminophen is unknown at this time.</p>
<p>Acetaminophen is rapidly and almost completely absorbed from the gastrointestinal tract.  In 24 normal volunteers the time to mean peak plasma concentration was 1 hour (range 0.25 to 3 hours) after oral administration and the mean plasma elimination half-life was 2.8 hours (range 2 to 4 hours).</p>
<p>The effect of pentazocine on acetaminophen plasma protein binding or vice versa has not been established.  For acetaminophen there is little or no plasma protein binding at normal therapeutic doses.  When toxic doses of acetaminophen are ingested and drug plasma levels exceed 90 mcg/mL, plasma binding may vary from 8% to 43%.</p>
<p>Acetaminophen is conjugated in the liver with glucuronic acid and to a lesser extent with sulfuric acid.  Approximately 80% of acetaminophen is excreted in the urine after conjugation and about 3% is excreted unchanged.  The drug is also conjugated to a lesser extent with cysteine and additionally metabolized by hydroxylation.</p>
<p>If TALACEN is taken every 4 hours over an extended period of time, accumulation of pentazocine and to a lesser extent, acetaminophen, may occur.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">TALACEN is indicated for the relief of mild to moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">TALACEN should not be administered to patients who are hypersensitive to either pentazocine or acetaminophen.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">As in the case of other potent analgesics, the potential of pentazocine for elevating cerebrospinal fluid pressure may be attributed to CO<span class="Sub">2</span> retention due to the respiratory depressant effects of the drug.  These effects may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a preexisting increase in intracranial pressure.  Furthermore, pentazocine can produce effects which may obscure the clinical course of patients with head injuries.  In such patients, TALACEN must be used with extreme caution and only if its use is deemed essential.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Acute CNS Manifestations</h2>
<p class="First">Patients receiving therapeutic doses of pentazocine have experienced <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (usually visual), <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> which have cleared spontaneously within a period of hours.  The mechanism of this reaction is not known.  Such patients should be closely observed and vital signs checked.  If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.</p>
<p>There have been instances of psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on parenteral pentazocine in patients with a history of drug abuse, and rarely, in patients without such a history. (See <a href="#Drug_Abuse_Dependence">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>.)</p>
<p>Due to the potential for increased CNS depressant effects, alcohol should be used with caution in patients who are currently receiving pentazocine.</p>
<p>Pentazocine may precipitate opioid abstinence symptoms in patients receiving courses of opiates for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Italics">In prescribing TALACEN for chronic use, the physician should take precautions to avoid increases in dose by the patient</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">As with all drugs, TALACEN should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> who have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Certain Respiratory Conditions</h2>
<p class="First">Although <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> has rarely been reported after oral administration of pentazocine, the drug should be administered with caution to patients with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> from any cause, severely limited respiratory reserve, severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and other obstructive respiratory conditions, or <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Impaired Renal or Hepatic Function</h2>
<p class="First">Decreased metabolism of the drug by the liver in extensive liver disease may predispose to accentuation of side effects. Although laboratory tests have not indicated that pentazocine causes or increases renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the drug should be administered with caution to patients with such impairment.</p>
<p>Since acetaminophen is metabolized by the liver, the question of the safety of its use in the presence of liver disease should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Biliary Surgery</h2>
<p class="First">Narcotic drug products are generally considered to elevate biliary tract pressure for varying periods following their administration.  Some evidence suggests that pentazocine may differ from other marketed narcotics in this respect (i.e., it causes little or no elevation in biliary tract pressures). The clinical significance of these findings, however, is not yet known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>CNS Effect</h2>
<p class="First">Caution should be used when TALACEN is administered to patients prone to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have occurred in a few such patients in association with the use of pentazocine although no cause and effect relationship has been established.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.6"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Since sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and occasional <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> have been noted, ambulatory patients should be warned not to operate machinery, drive cars, or unnecessarily expose themselves to hazards.  Pentazocine may cause physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> when taken alone and may have additive CNS depressant properties when taken in combination with alcohol or other CNS depressants.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.7"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Pentazocine is a mild narcotic antagonist. Some patients previously given narcotics, including methadone for the daily treatment of narcotic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, have experienced withdrawal symptoms after receiving pentazocine.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.8"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenesis, mutagenesis, and impairment of fertility studies have not been done with this combination product.</p>
<p>Pentazocine, when administered orally or parenterally, had no adverse effect on either the reproductive capabilities or the course of pregnancy in rabbits and rats.  Embryotoxic effects on the fetuses were not shown.</p>
<p>The daily administration of 4 mg/kg to 20 mg/kg pentazocine subcutaneously to female rats during a 14 day pre-mating period and until the 13th day of pregnancy did not have any adverse effects on the fertility rate.</p>
<p>There is no evidence in long-term animal studies to demonstrate that pentazocine is carcinogenic.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.9"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with TALACEN.  It is also not known whether TALACEN can cause fetal harm when administered to pregnant women or can affect reproduction capacity. TALACEN should be given to pregnant women only if clearly needed.  However, animal reproduction studies with pentazocine have not demonstrated teratogenic or embryotoxic effects.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.10"></a><p></p>
<h2>Nonteratogenic Effects</h2>
<p class="First">There has been no experience in this regard with the combination pentazocine and acetaminophen.  However, there have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.11"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Patients receiving pentazocine during labor have experienced no adverse effects other than those that occur with commonly used analgesics.  TALACEN should be used with caution in women delivering premature infants.  The effect of TALACEN on the mother and fetus, the duration of labor or delivery, the possibility that forceps delivery or other intervention or resuscitation of the newborn may be necessary, or the effect of TALACEN, on the later growth, development, and functional maturation of the child are unknown at the present time.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.12"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TALACEN is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.13"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.14"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of TALACEN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Clinical experience with TALACEN has been insufficient to define all possible adverse reactions with this combination.  However, reactions reported after oral administration of pentazocine hydrochloride in 50 mg dosage include <span class="Bold">gastrointestinal:</span>  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, infrequently <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; and rarely <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="Bold">CNS effects:</span>  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, sedation, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>; infrequently <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, disturbed dreams, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, visual blurring and focusing difficulty, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; and rarely <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. <span class="Bold">Autonomic:</span>  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; infrequently <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; and rarely <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>. <span class="Bold">Allergic:</span>  infrequently <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; and rarely <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the face. <span class="Bold">Cardiovascular</span>:  infrequently decrease in blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. <span class="Bold">Hematologic:</span>  rarely <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of white blood cells (especially granulocytes), which is usually reversible, moderate transient <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. <span class="Bold">Other:</span>  rarely <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and in one instance, an apparent <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> has been reported.</p>
<p>Numerous clinical studies have shown that acetaminophen, when taken in recommended doses, is relatively free of adverse effects in most age groups, even in the presence of a variety of disease states.</p>
<p>A few cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to acetaminophen have been reported, as manifested by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, rarely <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Occasional individuals respond to ordinary doses with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="Drug_Abuse_Dependence"></a><a name="section-10"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-10.1"></a><p></p>
<h2>Controlled Substance</h2>
<p class="First">TALACEN is a Schedule IV controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-10.2"></a><p></p>
<h2>Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">There have been some reports of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and of withdrawal symptoms with orally administered pentazocine.  There have been recorded instances of psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in patients using parenteral pentazocine.  Abrupt discontinuance following the extended use of parenteral pentazocine has resulted in withdrawal symptoms.  Patients with a history of <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> should be under close supervision while receiving TALACEN.  There have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine during pregnancy.</p>
<p>Some tolerance to the analgesic and subjective effects of pentazocine develops with frequent and repeated use.</p>
<p>Drug addicts who are given closely spaced doses of pentazocine (e.g., 60 mg to 90 mg every 4 hours) develop physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> which is demonstrated by abrupt withdrawal or by administration of naloxone.  The withdrawal symptoms exhibited after chronic doses of more than 500 mg of pentazocine per day have similar characteristics, but to a lesser degree, of opioid withdrawal and may be associated with <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug seeking behavior</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Manifestations</h2>
<p class="First">Clinical experience with TALACEN has been insufficient to define the signs of overdosage with this product. It may be assumed that signs and symptoms of TALACEN <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> would be a combination of those observed with pentazocine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>For pentazocine alone in single doses above 60 mg there have been reports of the occurrence of nalorphine-like psychotomimetic effects such as <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, strange thoughts, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>.  Marked <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> associated with <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> have also resulted from excessive doses as have <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>.  The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> is antagonized by naloxone (see <span class="Italics"><a href="#Treatment">Treatment</a></span>).</p>
<p>In acute acetaminophen overdosage, dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may also occur.</p>
<p>In adults, a single dose of 10 g to 15 g (200 mg/kg to 250 mg/kg) of acetaminophen may cause hepatotoxicity.  A dose of 25 g or more is potentially fatal.  The potential seriousness of the <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> may not be evident during the first two days of acute acetaminophen <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. During the first 24 hours, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> occur.  These may persist for a week or more.  <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver injury</span> may become evident the second day, initial signs being elevation of serum transaminase and lactic dehydrogenase activity, increased serum bilirubin concentration, and prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.  Serum albumin concentration and alkaline phosphatase activity may remain normal.  The hepatotoxicity may lead to <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Transient <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> is evident in a majority of patients and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> occurs in some.</p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> and impaired glucose tolerance, but <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may also occur.  <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span> have been reported.  <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral edema</span> and non-specific myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> have also been noted.  Biopsy reveals centrolobular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> with sparing of the periportal area.  The <span class="product-label-link" type="condition" conceptid="4104000" conceptname="Lesion of liver">hepatic lesions</span> are reversible over a period of weeks or months in nonfatal cases.</p>
<p>The severity of the <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> can be determined by measurement of the plasma halftime of acetaminophen during the first day of acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.  If the halftime exceeds 4 hours, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is likely and if the halftime is greater than 12 hours, <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> will probably occur.  Only minimal <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> has developed when the serum concentration was below 120 mcg/mL at 12 hours after ingestion of the drug. If serum bilirubin concentration is greater than 4 mg/100 mL during the first 5 days, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> may occur.</p>
<p>The seven day oral LD<span class="Sub">50</span> value for TALACEN in mice is 3,570 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Treatment"></a><a name="section-11.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.  For <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> due to overdosage or unusual sensitivity to TALACEN, parenteral naloxone is a specific and effective antagonist.</p>
<p>The toxic effects of acetaminophen may be prevented or minimized by antidotal therapy with N acetylcysteine. In order to obtain the best possible results, N-acetylcysteine should be administered as soon as possible.</p>
<p>Vigorous supportive therapy is required in severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.  Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.  Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or gastric lavage, followed by oral administration of activated charcoal should be done in all cases.</p>
<p>If hemodialysis can be initiated within the first 12 hours, it is advocated for patients with a plasma acetaminophen concentration exceeding 120 mcg/mL at 4 hours after ingestion of the drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>Adult</h2>
<p class="First">The usual adult dose is 1 caplet every 4 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief, up to a maximum of 6 caplets per day.</p>
<p>The usual duration of therapy is dependent upon the condition being treated but in any case should be reviewed regularly by the physician.  The effect of meals on the rate and extent of bioavailability of both pentazocine and acetaminophen has not been documented.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Talacen is available for oral administration as a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> blue, scored caplet embossed with "Winthrop" on one side and "T37" on the other side.</p>
<p>Bottles of 100 (NDC 0024-1937-04).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<h2></h2>
<p class="First">Store at 25° C (77° F); excursions permitted between 15° –  30° C (59° – 86° F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Revised August 2008</p>
<p>Manufactured for:<br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807</p>
<p>©2008 sanofi-aventis U.S. LLC</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TALACEN 		
					</strong><br><span class="contentTableReg">pentazocine hydrochloride and acetaminophen tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-1937</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pentazocine hydrochloride</strong> (pentazocine) </td>
<td class="formItem"></td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>acetaminophen</strong> (acetaminophen) </td>
<td class="formItem"></td>
<td class="formItem">650 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue #1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium sorbate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium metabisulfite</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">3mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Winthrop;T37</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-1937-04</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>F2BE08CB-1816-32C1-F344-E8AB22929041</div>
<div>Set id: 927F1BB9-6C13-4229-A5C8-0BF0B4C3BB35</div>
<div>Version: 4</div>
<div>Effective Time: 20081015</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
